Weight management drugs and high-cost specialty treatments are expected to have the biggest impact on private drug plans this year, according to Telus Health’s annual drug pipeline report. It found spending on weight management drugs has more than quadrupled since 2021. In 2024, the category doubled in size following the launch of Wegovy (semaglutide) in […]
The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]